微信关注
Total item
Cart Subtotal
￥ 0.00 JAK / Stat
-
XL019
Catalog No. A12394 -
Pyridone 6 (JAK Inhibitor I)
Catalog No. A13457 -
TG-02 (SB1317)
Catalog No. A11962 -
Cerdulatinib
Catalog No. A14210 multi-targeted tyrosine kinase 抑制剂Cerdulatinib (PRT-062070)是多靶点酪氨酸激酶抑制剂，对JAK1/JAK2/JAK3/TYK2和Syk的IC50分别为12 nM/6 nM/8 nM/0.5 nM和32 nM。 了解更多 -
Baricitinib phosphate
Catalog No. A15014 JAK 抑制剂Baricitinib phosphate是一种选择性的JAK1和JAK2抑制剂，IC50为5.9 nM和5.7 nM，选择性是JAK3和Tyk2的?70和?10倍，对c-Met和Chk2没有抑制作用。 了解更多 -
CHZ868
Catalog No. A15937 -
SB1317 (TG02)
Catalog No. A13454 CDK/JAK2/FLT3 抑制剂SB1317是细胞周期蛋白依赖性激酶（CDKs）、类FMS酪氨酸激酶-3（FLT3）和Janus激酶2（JAK2）的有效抑制剂，CDK2、JAK2和FLT3的IC50值分别为13nM、56nM和73nM。 了解更多 -
PF-06651600
Catalog No. A16803 JAK3 抑制剂PF-06651600是一种有效且不可逆的JAK3选择性抑制剂，IC50为33.1 nM，但对JAK1，JAK2和TYK2没有活性（IC50> 10 000 nM）。 了解更多 -
Ruxolitinib Phosphate
Catalog No. A11552 JAK 抑制剂Ruxolitinib Phosphate是ruxolitinib的磷酸盐形式，ruxolitinib是一种口服生物可利用的Janus相关激酶(JAK)抑制剂，具有潜在的抗肿瘤和免疫调节活性。 了解更多 -
PF-06700841 tosylate
Catalog No. A17176 -
JAK3-IN-2
Catalog No. A18323 JAK3 抑制剂JAK3-IN-2 is a potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM. dispalys >4,300-fold selectivity over JAK1, JAK2 and TYK2, and other kinases BMX, EGFR, ITK and BTK; blocks cytokine signaling through JAK3, but not through other JAK family enzymes; inhibits IL-7 induced pSTAT5 in CD3+, CD8+ T cells with IC50 of 280 nM; sufficiently blocks the development of inflammation in a rat model of rheumatoid arthritis, while sparing hematopoiesis. 了解更多 -
Abrocitinib (PF-04965842)
Catalog No. A18318 JAK1 抑制剂Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease. 了解更多 -
Upadacitinib (ABT-494)
Catalog No. A18316 JAK-1 抑制剂Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. IC50 & Target: IC50: 43 nM (JAK1), 200 nM (JAK2) 了解更多 -
BMS-986165
Catalog No. A18726 TYK2 抑制剂BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2. BMS-986165 Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease. 了解更多 -
JAK3 covalent inhibitor-1
Catalog No. A18926 JAK3 covalent 抑制剂JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. 了解更多 -
Tofacitinib
Catalog No. A17252 JAK3/2/1 inhibitorTofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. 了解更多 -
PF-06263276
Catalog No. A12572 pan-JAK inhibitorPF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. 了解更多 -
Ruxolitinib sulfate
Catalog No. A11467 JAK1/2 inhibitorRuxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3. 了解更多 -
JAK/HDAC-IN-1
Catalog No. A13362 JAK2/HDAC dual inhibitorJAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. 了解更多 -
Oclacitinib maleate
Catalog No. A16640 JAK inhibitorOclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM). 了解更多 -
NVP-BSK805 dihydrochloride
Catalog No. A21406 JAK2 inhibitorNVP-BSK805 dihydrochloride (BSK805 dihydrochloride) is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively. 了解更多 -
PF-06700841 P-Tosylate
Catalog No. A21652 dual JAK1/TYK2 inhibitorPF-06700841 P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. 了解更多 -
Momelotinib Mesylate
Catalog No. A21658 JAK1/JAK2 inhibitorMomelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. 了解更多 -
PRT 062070 (Cerdulatinib)
Catalog No. A14147 Dual Syk and JAK 抑制剂PRT 062070 (Cerdulatinib)是一种新型的口服双脾酪氨酸激酶（Syk）和janus激酶（JAK）抑制剂。Cerdulatinib优先抑制各种细胞类型中JAK1和JAK3依赖性细胞因子介导的信号传导和功能性反应。 了解更多 -
NSC 42834(JAK2 Inhibitor V, Z3)
Catalog No. A14132 -
Filgotinib
Catalog No. A14232 JAK 抑制剂Filgotinib是一种选择性的JAK1抑制剂，对于JAK1，JAK2，JAK3和TYK2的IC50分别为10 nM，28 nM，810 nM和116 nM。 了解更多 -
Solcitinib (GSK2586184)
Catalog No. A14405 -
Decernotinib
Catalog No. A14012 -
ZM 39923 HCl
Catalog No. A13509 JAK3 抑制剂ZM 39923 HCl是JAK3抑制剂（IC50 = 79 nM），其抑制表皮生长因子受体，JAK1和细胞周期蛋白依赖性激酶4（IC50s分别为2.4、40和10 M）的抑制作用较小。 了解更多 -
S-Ruxolitinib
Catalog No. A14955 -
CYT387 sulfate salt
Catalog No. A15056 -
1,2,3,4,5,6-Hexabromocyclohexane
Catalog No. A15361 -
Cercosporamide
Catalog No. A15362 Mnk2/JAK3 抑制剂Cercosporamide是一种USnic酰胺，最初在Cercosporidium henningsii中被鉴定为宿主选择性植物毒素和广谱抗真菌剂，并且是MAP激酶相互作用激酶2（Mnk2；IC50 = 11 nM），JAK3（IC50 = 31）和Mnk1（IC50 = 116 nM）。 了解更多 -
Cucurbitacin I
Catalog No. A15363 JAK2/STAT3 抑制剂Cucurbitacin I（Cucumis sativus L.）可以抑制v-Src转化的NIH 3T3细胞中的磷酸酪氨酸Stat3（信号转导和转录激活因子3）水平。 了解更多
FILTER BY:
购物选项
- 分类
- 作用机制
-
- Inhibitor (抑制剂) (209)
- Activator (激活剂) (1)
- Inducer (诱导剂) (1)
- 靶点
-
- Aurora A (1)
- Aurora B (1)
- CDK (2)
- CDK2 (1)
- CDK4 (1)
- DNMT (1)
- EGFR (24)
- EGFR Exon 19 Deletion (1)
- EGFR L858R (5)
- EGFR L861Q (2)
- EGFR T790M (9)
- EGFR wild type (2)
- ErbB2 (3)
- ErbB3 (1)
- ErbB4 (2)
- FGFR1 (1)
- FLT3 (6)
- HDAC (1)
- HER2 (2)
- JAK1 (18)
- JAK2 (37)
- JAK3 (17)
- Mnk1 (1)
- Mnk2 (1)
- PDGFRβ (1)
- Pim1 (9)
- Pim2 (7)
- Pim3 (5)
- PKCα (1)
- PKCβ (1)
- RET (1)
- STAT1 (1)
- STAT3 (7)
- STAT5 (2)
- Syk (2)
- Tyk2 (5)
- VEGFR2 (FLK1) (2)
- VEGFR3 (FLT4) (1)
ADOOQ 产品质量保证
We promise all products to perform as described.